The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.
Francesco Massari
No relevant relationships to disclose
Francesca Maines
No relevant relationships to disclose
Sara Pilotto
No relevant relationships to disclose
Camillo Porta
No relevant relationships to disclose
Paolo Carlini
No relevant relationships to disclose
Alessandra Modena
No relevant relationships to disclose
Chiara Ciccarese
No relevant relationships to disclose
Isabella Sperduti
No relevant relationships to disclose
Diana Giannarelli
No relevant relationships to disclose
Giampaolo Tortora
No relevant relationships to disclose
Emilio Bria
No relevant relationships to disclose